It has been recently proposed that the two "emerging" hallmarks of cancer, namely altered glucose metabolism and immune evasion, may in fact be fundamentally linked (Kareva and Hahnfeldt, 2013). This connection comes from up-regulation of glycolysis by tumor cells, which can lead to active competition for resources in the tumor microenvironment between tumor and immune cells. Here it is further proposed that cancer stem cells (CSCs) can circumvent the anti-tumor immune response by creating a 'protective shield' of non-stem cancer cells around them. This shield can protect the CSCs both by creating a physical barrier between them and cytotoxic lymphocytes (CTLs), and by promoting competition for the common resources, such as glucose, between non-stem cancer cells and CTLs. The implications of this hypothesis are investigate using an agent-based model, leading to a prediction that relative CSC to non-CSC ratio will vary with the strength of the host immune response, with the highest occurring at an intermediate state of immune activation. A discussion of possible therapeutic approaches concludes the paper, suggesting that a chemotherapeutic regimen consisting of regular pulsed doses, i.e., metronomic chemotherapy, would yield the best clinical outcome by allowing CTLs to most effectively reach and eliminate CSCs.